Julie Rubinstein - 06 Mar 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
President and COO
Signature
/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
06 Mar 2026
Net transactions value
-$1,211,737
Form type
4
Filing time
10 Mar 2026, 20:04:33 UTC
Previous filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RUBINSTEIN JULIE President and COO C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE /s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact 10 Mar 2026 0001780664

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise +14,722 +2.2% $6.55* 671,207 06 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +11,881 +1.8% $12.14* 683,088 06 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $468,447 -30,941 -4.5% $15.14 652,147 06 Mar 2026 Direct F1, F2
transaction ADPT Common Stock Options Exercise +14,722 +2.3% $6.55* 666,869 09 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +11,881 +1.8% $12.14* 678,750 09 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $457,617 -30,941 -4.6% $14.79 647,809 09 Mar 2026 Direct F1, F3
transaction ADPT Common Stock Options Exercise +14,722 +2.3% $6.55* 662,531 10 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +400 +0.06% $12.14* 662,931 10 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $285,673 -19,460 -2.9% $14.68 643,471 10 Mar 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -9.7% $0.000000* 136,437 06 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise -11,881 -2.8% $0.000000* 415,820 06 Mar 2026 Common Stock 11,881 $12.14 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -11% $0.000000* 121,715 09 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise -11,881 -2.9% $0.000000* 403,939 09 Mar 2026 Common Stock 11,881 $12.14 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -12% $0.000000* 106,993 10 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F5
transaction ADPT Stock Option (right to buy) Options Exercise -400 -0.1% $0.000000* 403,539 10 Mar 2026 Common Stock 400 $12.14 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $15.15, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.22 to $15.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The option is fully vested and exercisable.